Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
57
EXAS Quote, Financials, Valuation and Earnings
Last price:
$101.55
Seasonality move
:
13.8%
Day range:
$101.49 - $101.65
52-week range:
$38.81 - $102.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.18x
P/B ratio:
7.69x
Volume:
400.7K
Avg. volume:
8.4M
1-year change:
74.74%
Market cap:
$19.2B
Revenue:
$2.8B
EPS (TTM):
-$5.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EXAS
EXACT Sciences Corp.
|
$810.6M | $0.16 | 20.69% | -84.17% | $104.56 |
|
DGX
Quest Diagnostics, Inc.
|
$2.7B | $2.50 | 5.05% | 21.08% | $198.06 |
|
FLGT
Fulgent Genetics, Inc.
|
$81.4M | -$0.22 | 12.03% | -53.46% | $33.67 |
|
GH
Guardant Health, Inc.
|
$235.7M | -$0.49 | 32.68% | -47.37% | $114.05 |
|
ILMN
Illumina, Inc.
|
$1.1B | $1.17 | -0.1% | 4.82% | $125.28 |
|
NTRA
Natera, Inc.
|
$514.8M | -$0.35 | 21.14% | -42.93% | $246.26 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EXAS
EXACT Sciences Corp.
|
$101.54 | $104.56 | $19.2B | -- | $0.00 | 0% | 6.18x |
|
DGX
Quest Diagnostics, Inc.
|
$175.92 | $198.06 | $19.6B | 20.64x | $0.80 | 1.79% | 1.83x |
|
FLGT
Fulgent Genetics, Inc.
|
$27.01 | $33.67 | $834.9M | -- | $0.00 | 0% | 2.63x |
|
GH
Guardant Health, Inc.
|
$102.38 | $114.05 | $13.3B | -- | $0.00 | 0% | 14.08x |
|
ILMN
Illumina, Inc.
|
$136.19 | $125.28 | $20.8B | 30.51x | $0.00 | 0% | 5.01x |
|
NTRA
Natera, Inc.
|
$235.40 | $246.26 | $32.8B | -- | $0.00 | 0% | 15.01x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EXAS
EXACT Sciences Corp.
|
50.33% | 1.709 | 24.46% | 2.24x |
|
DGX
Quest Diagnostics, Inc.
|
46.79% | 0.203 | 30.05% | 0.90x |
|
FLGT
Fulgent Genetics, Inc.
|
0.71% | -0.040 | 1.15% | 6.47x |
|
GH
Guardant Health, Inc.
|
136.47% | 1.840 | 16.98% | 2.94x |
|
ILMN
Illumina, Inc.
|
51.97% | 2.433 | 17.73% | 1.04x |
|
NTRA
Natera, Inc.
|
13.7% | 1.342 | 0.9% | 3.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EXAS
EXACT Sciences Corp.
|
$583.9M | $16.3M | -18.87% | -38% | 1.91% | $190M |
|
DGX
Quest Diagnostics, Inc.
|
$911M | $420M | 7.41% | 14.33% | 14.92% | $419M |
|
FLGT
Fulgent Genetics, Inc.
|
$33.5M | -$15.4M | -3.9% | -3.93% | -18.26% | $5.1M |
|
GH
Guardant Health, Inc.
|
$171.6M | -$99M | -36.05% | -8518.58% | -37.33% | -$45.8M |
|
ILMN
Illumina, Inc.
|
$732M | $231M | 14.3% | 30.55% | 21.33% | $253M |
|
NTRA
Natera, Inc.
|
$384.4M | -$97.6M | -21.88% | -26.6% | -16.48% | $24.5M |
EXACT Sciences Corp. vs. Competitors
-
Which has Higher Returns EXAS or DGX?
Quest Diagnostics, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of 9.13%. EXACT Sciences Corp.'s return on equity of -38% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.
Company Gross Margin Earnings Per Share Invested Capital EXASEXACT Sciences Corp.68.64% -$0.10 $5B DGXQuest Diagnostics, Inc.32.35% $2.15 $13.8B -
What do Analysts Say About EXAS or DGX?
EXACT Sciences Corp. has a consensus price target of $104.56, signalling upside risk potential of 2.98%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $198.06 which suggests that it could grow by 12.59%. Given that Quest Diagnostics, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Quest Diagnostics, Inc. is more attractive than EXACT Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings EXASEXACT Sciences Corp.3 18 0 DGXQuest Diagnostics, Inc.7 10 0 -
Is EXAS or DGX More Risky?
EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.214%.
-
Which is a Better Dividend Stock EXAS or DGX?
EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.79% to investors and pays a quarterly dividend of $0.80 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios EXAS or DGX?
EXACT Sciences Corp. quarterly revenues are $850.7M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. EXACT Sciences Corp.'s net income of -$19.6M is lower than Quest Diagnostics, Inc.'s net income of $257M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Quest Diagnostics, Inc.'s PE ratio is 20.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.18x versus 1.83x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EXASEXACT Sciences Corp.6.18x -- $850.7M -$19.6M DGXQuest Diagnostics, Inc.1.83x 20.64x $2.8B $257M
-
Which has Higher Returns EXAS or FLGT?
Fulgent Genetics, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of -8.12%. EXACT Sciences Corp.'s return on equity of -38% beat Fulgent Genetics, Inc.'s return on equity of -3.93%.
Company Gross Margin Earnings Per Share Invested Capital EXASEXACT Sciences Corp.68.64% -$0.10 $5B FLGTFulgent Genetics, Inc.39.83% -$0.21 $1.1B -
What do Analysts Say About EXAS or FLGT?
EXACT Sciences Corp. has a consensus price target of $104.56, signalling upside risk potential of 2.98%. On the other hand Fulgent Genetics, Inc. has an analysts' consensus of $33.67 which suggests that it could grow by 24.65%. Given that Fulgent Genetics, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Fulgent Genetics, Inc. is more attractive than EXACT Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings EXASEXACT Sciences Corp.3 18 0 FLGTFulgent Genetics, Inc.1 1 0 -
Is EXAS or FLGT More Risky?
EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Fulgent Genetics, Inc. has a beta of 0.648, suggesting its less volatile than the S&P 500 by 35.159%.
-
Which is a Better Dividend Stock EXAS or FLGT?
EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulgent Genetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Fulgent Genetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EXAS or FLGT?
EXACT Sciences Corp. quarterly revenues are $850.7M, which are larger than Fulgent Genetics, Inc. quarterly revenues of $84.1M. EXACT Sciences Corp.'s net income of -$19.6M is lower than Fulgent Genetics, Inc.'s net income of -$6.8M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Fulgent Genetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.18x versus 2.63x for Fulgent Genetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EXASEXACT Sciences Corp.6.18x -- $850.7M -$19.6M FLGTFulgent Genetics, Inc.2.63x -- $84.1M -$6.8M
-
Which has Higher Returns EXAS or GH?
Guardant Health, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of -34.97%. EXACT Sciences Corp.'s return on equity of -38% beat Guardant Health, Inc.'s return on equity of -8518.58%.
Company Gross Margin Earnings Per Share Invested Capital EXASEXACT Sciences Corp.68.64% -$0.10 $5B GHGuardant Health, Inc.64.71% -$0.74 $971.9M -
What do Analysts Say About EXAS or GH?
EXACT Sciences Corp. has a consensus price target of $104.56, signalling upside risk potential of 2.98%. On the other hand Guardant Health, Inc. has an analysts' consensus of $114.05 which suggests that it could grow by 11.4%. Given that Guardant Health, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Guardant Health, Inc. is more attractive than EXACT Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings EXASEXACT Sciences Corp.3 18 0 GHGuardant Health, Inc.17 0 0 -
Is EXAS or GH More Risky?
EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Guardant Health, Inc. has a beta of 1.579, suggesting its more volatile than the S&P 500 by 57.876%.
-
Which is a Better Dividend Stock EXAS or GH?
EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Guardant Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EXAS or GH?
EXACT Sciences Corp. quarterly revenues are $850.7M, which are larger than Guardant Health, Inc. quarterly revenues of $265.2M. EXACT Sciences Corp.'s net income of -$19.6M is higher than Guardant Health, Inc.'s net income of -$92.7M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Guardant Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.18x versus 14.08x for Guardant Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EXASEXACT Sciences Corp.6.18x -- $850.7M -$19.6M GHGuardant Health, Inc.14.08x -- $265.2M -$92.7M
-
Which has Higher Returns EXAS or ILMN?
Illumina, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of 13.85%. EXACT Sciences Corp.'s return on equity of -38% beat Illumina, Inc.'s return on equity of 30.55%.
Company Gross Margin Earnings Per Share Invested Capital EXASEXACT Sciences Corp.68.64% -$0.10 $5B ILMNIllumina, Inc.67.59% $0.97 $5B -
What do Analysts Say About EXAS or ILMN?
EXACT Sciences Corp. has a consensus price target of $104.56, signalling upside risk potential of 2.98%. On the other hand Illumina, Inc. has an analysts' consensus of $125.28 which suggests that it could fall by -8.01%. Given that EXACT Sciences Corp. has higher upside potential than Illumina, Inc., analysts believe EXACT Sciences Corp. is more attractive than Illumina, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EXASEXACT Sciences Corp.3 18 0 ILMNIllumina, Inc.7 8 1 -
Is EXAS or ILMN More Risky?
EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.845%.
-
Which is a Better Dividend Stock EXAS or ILMN?
EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EXAS or ILMN?
EXACT Sciences Corp. quarterly revenues are $850.7M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. EXACT Sciences Corp.'s net income of -$19.6M is lower than Illumina, Inc.'s net income of $150M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 30.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.18x versus 5.01x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EXASEXACT Sciences Corp.6.18x -- $850.7M -$19.6M ILMNIllumina, Inc.5.01x 30.51x $1.1B $150M
-
Which has Higher Returns EXAS or NTRA?
Natera, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of -14.78%. EXACT Sciences Corp.'s return on equity of -38% beat Natera, Inc.'s return on equity of -26.6%.
Company Gross Margin Earnings Per Share Invested Capital EXASEXACT Sciences Corp.68.64% -$0.10 $5B NTRANatera, Inc.64.91% -$0.64 $1.5B -
What do Analysts Say About EXAS or NTRA?
EXACT Sciences Corp. has a consensus price target of $104.56, signalling upside risk potential of 2.98%. On the other hand Natera, Inc. has an analysts' consensus of $246.26 which suggests that it could grow by 4.62%. Given that Natera, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Natera, Inc. is more attractive than EXACT Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings EXASEXACT Sciences Corp.3 18 0 NTRANatera, Inc.12 2 0 -
Is EXAS or NTRA More Risky?
EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.628, suggesting its more volatile than the S&P 500 by 62.801%.
-
Which is a Better Dividend Stock EXAS or NTRA?
EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EXAS or NTRA?
EXACT Sciences Corp. quarterly revenues are $850.7M, which are larger than Natera, Inc. quarterly revenues of $592.2M. EXACT Sciences Corp.'s net income of -$19.6M is higher than Natera, Inc.'s net income of -$87.5M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.18x versus 15.01x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EXASEXACT Sciences Corp.6.18x -- $850.7M -$19.6M NTRANatera, Inc.15.01x -- $592.2M -$87.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
